@article{Santos-Sánchez2024, 
author = {Guillermo Santos-Sánchez and Ana Isabel Álvarez-López and Eduardo Ponce-España and Patricia Judith Lardone and Antonio Carrillo-Vico and Ivan Cruz-Chamorro},
title = {Food-derived peptides with inhibitory capacity for HMG-CoA reductase activity: a potential nutraceutical for hypercholesterolemia},
year = {2024},
journal = {Food Science and Human Wellness},
volume = {13},
number = {6},
pages = {3083-3094},
keywords = {Functional foods, Cholesterol, Cardiovascular diseases, Statins, 3-Hydroxy-3-methylglutaryl-coenzyme A},
url = {https://www.sciopen.com/article/10.26599/FSHW.2023.9250001},
doi = {10.26599/FSHW.2023.9250001},
abstract = {Cardiovascular diseases (CVDs) are the leading global cause of mortality and disease burden. Statins are the most prescribed lipid-lowering drugs to treat hypercholesterolemia and prevent CVDs. The biochemical mechanism of statins consists of competitive inhibition of the 3-hydroxy-3-methylglutaryl-coenzyme A reductase enzyme (HMG-CoAR), the limiting enzyme in cholesterol biosynthesis. Due to statin intolerance in some patient groups, the search for new inhibitors is a field of great interest. This review focusses on the studies reporting the inhibitory effect of protein hydrolysates and biopeptides on the HMG-CoAR enzyme activity. The analysis of the action mechanism and physicochemical characteristics of the HMG-CoAR inhibitory peptides revealed that the molecular weight, amino acid composition, charge, and polarity are key aspects of the interaction with the HMG-CoAR enzyme. In conclusion, this review reveals the potential of using food peptides as new cholesterol-lowering agents and opens a new interesting field of research. However, clinical approaches are mandatory to confirm their therapeutic hypercholesterolemic effect.}
}